• Aucun résultat trouvé

Pandoraea pulmonicola chronic colonization in a cystic fibrosis patient, France

N/A
N/A
Protected

Academic year: 2021

Partager "Pandoraea pulmonicola chronic colonization in a cystic fibrosis patient, France"

Copied!
4
0
0

Texte intégral

(1)

HAL Id: hal-01478609

https://hal-amu.archives-ouvertes.fr/hal-01478609

Submitted on 6 Nov 2020

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of

sci-entific research documents, whether they are

pub-lished or not. The documents may come from

teaching and research institutions in France or

abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est

destinée au dépôt et à la diffusion de documents

scientifiques de niveau recherche, publiés ou non,

émanant des établissements d’enseignement et de

recherche français ou étrangers, des laboratoires

publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial| 4.0 International

License

Pandoraea pulmonicola chronic colonization in a cystic

fibrosis patient, France

S. Kokcha, F. Bittar, M. Gaubert, L. Mely, C. Gomez, J.-Y. Gaubert, P.

Thomas, Jean-Marc Rolain

To cite this version:

S. Kokcha, F. Bittar, M. Gaubert, L. Mely, C. Gomez, et al.. Pandoraea pulmonicola chronic

colo-nization in a cystic fibrosis patient, France. New Microbes and New Infections, Wiley Online Library

2013, 1 (2), pp.27 - 29. �10.1002/2052-2975.16�. �hal-01478609�

(2)

Pandoraea pulmonicola chronic

colonization in a cystic fibrosis

patient, France

S. Kokcha1, F. Bittar1, M. Reynaud-Gaubert1,2, L. Mely3, C. Gomez2, J.-Y. Gaubert4, P. Thomas5and J.-M. Rolain1

1) P^ole des Maladies Infectieuses, Assistance Publique-H^opitaux de Marseille et URMITE UMR CNRS-IRD 6236, IFR48, Faculte de Medecine et de Pharmacie, Universite de la Mediterranee, 2) Service de Pneumologie et de Transplantation Pulmonaire, H^opital Nord, Marseille, 3) Centre de Ressources et de Competences pour la Mucoviscidose (CRCM), H^opital Renee Sabran, Hyeres, 4) Service de Radiologie adulte, H^opital de la Timone and 5) Service de Chirurgie Thoracique et Transplantation Pulmonaire, H^opital Nord, Marseille, France

Abstract

Pandoraea are considered emerging multidrug resistant pathogens in the context of cystic fibrosis. We report herein for the first time the case of a 30-year-old woman with cystic fibrosis, living in France, who was chronically infected with Pandoraea pulmonicola and who died of Pseudomonas aeruginosa sepsis 3 weeks after bilateral lung transplantation.

Keywords: Antibiotic resistance, lung transplantation, multi-drug resistant bacteria, Pandoraea, pulmonary infection

Original Submission: 7 June 2013; Accepted: 2 August 2013 Article published online: 30 September 2013

New Microbe New Infect 2013; 1: 27–29

Corresponding author: J.-M. Rolain, URMITE, CNRS-IRD UMR 6236, Faculte de Medecine et de Pharmacie, 27 Boulevard Jean Moulin, 13385 Marseille Cedex 5, France.

E-mail: Jean-marc.rolain@univmed.fr

Introduction

Pandoraea species are non-fermentative, Gram-negative bac-teria that are considered emerging multi-drug resistant pathogens in the context of cystic fibrosis (CF) [1]. The genus Pandoraea was created in 2000 and now comprises at least five validated species, i.e. Pandoraea apista, P. norimberg-ensis, P. pnomenusa, P. pulmonicola and P. sputorum [1] (Fig. 1). Conventional phenotypic laboratory methods remain prob-lematic for the accurate identification of these bacteria at the

species level and misidentification with bacteria of the genus Burkholderia and Ralstonia has been reported [2]. Although these bacteria are emerging pathogens in CF patients, there are very few clinical data on the clinical course and outcomes for patients colonized with these bacteria especially in the context of lung transplantation [2]. We report herein for the first time the case of a 30-year-old woman with CF, living in France, who was chronically co-infected with P. pulmonicola and Pseudomonas aeruginosa and who died of P. aeruginosa sepsis 3 weeks after bilateral lung transplantation (BLT).

Case Report

A 30-year-old woman who was diagnosed with CF at 3 months of age with a homozygous ΔF508 mutation had been infected with P. pulmonicola at least since October 2009. She was also chronically infected with P. aeruginosa and was placed on the active waiting list for BLT from January 2009. From October 2008 to March 2010, the patient had a dramatic deterioration of her pulmonary functional tests with a chronically persistent septic status and intermittent fever. During this period, apart from P. aeruginosa (resistant to all antibiotics except colistin), a colistin-resistant Gram-negative bacterium was isolated seven times from Cepacia agar. P. pulmonicola was eventually identified by routine analysis by matrix assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF) [3] and confirmed with 16S rDNA gene sequence analysis (99.9% of similarity with GenBank acces-sion number AF139175) (Strain 9405935, Fig. 1). The susceptibility profile of this organism demonstrated that the organism was initially susceptible only to tigecycline and rifampin, and resistant to ticarcillin, ticarcillin/clavulanic acid, tazocillin, ceftazidime, imipenem, gentamycin, tobramycin, fosfomycin, rifampin, trimethoprim/sulfamethoxazole, colistin, ciprofloxacin and cefpirome.

In March 2010 the patient was admitted to the adult CF reference centre in Marseille for persistent haemoptysis and worsening of pulmonary infection. On examination she had fever (38°C), and had lost 4 kg in weight during the previous 6 months. She presented stage III NYHA dyspnoea, cough and purulent expectoration. Axial lung computed tomography (CT) scan showed a large parenchymal cavity that occupied almost all the right upper lobe, with a thick lobulated wall (maximum thickness 7.5 mm) interpreted as an infarct pneu-monia (Fig. 2A). Relevant laboratory findings included a white blood cell count of 17, 78 G/L, a platelet count of 405 G/L, C-reactive protein at 36 mg/L, and fibrinogen at 4.8 g/L. She had a new procedure of therapeutic bronchial artery

embo-ª 2013 The Authors. New Microbes and New Infections published by John Wiley & Sons Ltd on behalf of the European Society of Clinical Microbiology and Infectious Diseases This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

NEW MICROBES IN HUMANS-NEW RESISTANT MICROBES IN HUMANS 10.1002/2052-2975.16

(3)

lization and an intravenous antibiotherapy with tigecycline 50 mg 9 2/day, colistin 2M 9 3/day, meropenem 2 g 9 3/ day and tobramycin 450 mg/day was started. The patient received continuous oxygen therapy and intermittent non-invasive ventilation but there was poor progress after 14 days with such therapy. The patient finally underwent BLT 3 weeks after her admission. Her condition worsened 5 days after lung transplantation and P. aeruginosa was isolated from blood cultures, lymph nodes, bronchoalveolar lavage, liquid drains and pleural liquid whereas P. pulmonicola was cultured only from one bronchoalveolar lavage on postoperative day 19. A CT scan of the lung showed diffuse bilateral alveolar

opacities and a parenchymal cavity 40 mm in diameter in the left upper lobe (Fig. 2B). The patient died 3 weeks after the BLT from multi-organ failure in septic shock despite intrave-nous antibiotherapy.

Conclusions

During the last decade, many new and/or emerging multidrug resistant pathogens (especially bacteria resistant to colistin) have been described in CF patients including Burkholderia cepacia complex, Inquilinus limosus [4], Acetobacter indonesiensis

FIG. 1. Phylogenetic tree based on 16S rDNA sequences showing the taxonomic position of bacteria of the genus Pandoraea

(a) (b)

FIG. 2. Lung CT obtained before the lung transplantation (A) and 3 weeks after lung transplantation (B) showing large parenchymal cavity and bilateral alveolar opacities.

ª 2013 The Authors. New Microbes and New Infections published by John Wiley & Sons Ltd on behalf of the European Society of Clinical Microbiology and Infectious Diseases, NMNI, 1, 27–29

28 New Microbes and New Infections, Volume 1 Number 2, November 2013

NMNI

(4)

[5], Brevundimonas diminuta, Ochrobactrum anthropi [6], and bacteria of the genus Pandoraea [7] (Fig. 1) suggesting that these bacteria may be selected during therapy with colistin for chronic colonization with P. aeruginosa. This hypothesis is strongly supported for Pandoraea species since in all published cases, CF patients were co-colonized with P. aeruginosa [2,8– 10]. In our report we eventually identified P. pulmonicola by a molecular method and also we have demonstrated the accuracy and usefulness of MALDI-TOF as a routine technique for rapid identification of this bacterium as previously described [3,11]. The pathogenicity of Pandoraea species remains controversial and there are only a few reports concerning lung transplant patients in the literature. However, there is evidence of lung function decline as well as patient--to-patient transmission of these bacteria in CF patients, at least for P. apista [8]. Whether this bacterium has contributed to the poor outcome of the patient before and/or after BLT remains unclear since P. aeruginosa was also repeatedly isolated during this period and our patient eventually died of P. aeruginosa sepsis. In our review of the literature we found only four cases of transplantation in CF patients chronically colonized with bacteria of the genus Pandoraea [2] including three cases of P. apista (one case from Denmark and two cases from the USA), and one case of P. pulmonicola from Ireland. In the case report from Australia, one CF patient was chronically colonized by P. sputorum and this patient was not considered to be a suitable candidate for transplantation [2]. For the four CF transplanted patients reviewed, the three patients previ-ously colonized with P. apista and the patient with P. pulmonicola survived after BLT. There is only one case of a 30-year-old man suffering from end-stage pulmonary sarcoid-osis who died from P. pnomenusa sepsis after lung transplan-tation, suggesting that Pandoraea species may lead to severe infections in patients with chronic lung diseases [12]. To the best of our knowledge, our case of a CF patient chronically colonized with P. pulmonicola is the first human case reported from France. The lack of available effective antibiotics for the treatment of such infections due to the pan-resistant pheno-type and the possibility of transmission between patients re-emphasizes the need to implement control strategy policies

to protect the CF community, especially contact isolation procedures during follow-up visits and hospitalizations [8].

References

1. Coenye T, Liu L, Vandamme P, Lipuma JJ. Identification of Pandoraea species by 16S ribosomal DNA-based PCR assays. J Clin Microbiol 2001; 39: 4452–4455.

2. Pimentel JD, MacLeod C. Misidentification of Pandoraea sputorum isolated from sputum of a patient with cystic fibrosis and review of Pandoraea species infections in transplant patients. J Clin Microbiol 2008; 46: 3165–3168.

3. Seng P, Drancourt M, Gouriet F, La Scola B, Fournier PE, Rolain JM et al. On-going revolution in bacteriology: routine identification by matrix-assisted laser desorption ionization time-of-flight mass spec-trometry. Clin Infect Dis 2009; 49: 543–551.

4. Bittar F, Leydier A, Bosdure E, Toro A, Boniface S, Stremler N et al. Inquilinus limosus and cystic fibrosis. Emerg Infect Dis 2008; 14: 993–995. 5. Bittar F, Reynaud-Gaubert M, Thomas P, Boniface S, Raoult D, Rolain JM. Acetobacter indonesiensis pneumonia after lung transplant. Emerg Infect Dis 2008; 14: 997–998.

6. Menuet M, Bittar F, Stremler N, Dubus JC, Sarles J, Raoult D et al. First isolation of two colistin-resistant emerging pathogens, Brevundimonas diminuta and Ochrobactrum anthropi, in a woman with cystic fibrosis: a case report. J Med Case Rep 2008; 2: 373.

7. Bittar F, Rolain JM. Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients. Clin Microbiol Infect 2010; 16: 809–820.

8. Jorgensen IM, Johansen HK, Frederiksen B, Pressler T, Hansen A, Vandamme P et al. Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol 2003; 36: 439–446.

9. Atkinson RM, Lipuma JJ, Rosenbluth DB, Dunne WM Jr. Chronic colonization with Pandoraea apista in cystic fibrosis patients determined by repetitive-element-sequence PCR. J Clin Microbiol 2006; 44: 833–836. 10. Perez dA-B, Buendia-Moreno B, Giron-Moreno RM, Lopez-Brea M. Pandoraea pulmonicola isolation in patients with cystic fibrosis. Enferm Infecc Microbiol Clin 2006; 24: 473–474.

11. Degand N, Carbonnelle E, Dauphin B, Beretti JL, Le BM, Ser-met-Gaudelus I et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of nonfermenting gram-negative bacilli isolated from cystic fibrosis patients. J Clin Microbiol 2008; 46: 3361–3367.

12. Stryjewski ME, Lipuma JJ, Messier RH Jr, Reller LB, Alexander BD. Sepsis, multiple organ failure, and death due to Pandoraea pnomenusa infection after lung transplantation. J Clin Microbiol 2003; 41: 2255– 2257.

ª 2013 The Authors. New Microbes and New Infections published by John Wiley & Sons Ltd on behalf of the European Society of Clinical Microbiology and Infectious Diseases, NMNI, 1, 27–29

NMNI

S. Kokcha et al. Pandoraea pulmonicola and Cystic Fibrosis 29

Figure

FIG. 2. Lung CT obtained before the lung transplantation (A) and 3 weeks after lung transplantation (B) showing large parenchymal cavity and bilateral alveolar opacities.

Références

Documents relatifs

The combination of (a) technical mechanisms in terms of architectural considerations, (b) social-economic aspects in terms of individualized services and tariffs., and (c) eco-

On avait en conséquence saisi un Biscayen convaincu d'avoir épousé sa commère, et deux Portugais qui en mangeant un poulet en avaient arraché le lard : on vint lier après le dîner

In the current study, it was hypothesized that adolescents with psychosis or with high risk would be able to successfully complete the CACR program and would show

This study highlights that the time trends observed in the incidence rate depend on the health policies imple- mented in the studied population (i.e. newborn screen- ing,

Because of the small differences in root overlap between S levels and the limited potential of extra water extraction due to the absence of a water table, we speculate that

In this French nationwide study, we investigated the epidemiological characteristics and genotype distribution of hepatitis C virus (HCV) in treat- ment-naive patients with

However, it is widely accepted that patients may make significant contributions to non-clinical aspects of care [3]. Many opportunities have been identified for patients to

Keywords: Pneumocystis jirovecii, Pneumocystis pneumonia, cystic fibrosis, pulmonary colonization, genomic diversity, microbiota, Pneumocystis primary infection, lung